Industry news that matters to you.  Learn more

The Scientist Webinar: Tackling the Challenges Involved with Protein Biomarkers

Protein biomarkers have been hailed as vital stepping stones in the race to personalize medicine. But many hurdles remain to be cleared before their application becomes routine. Currently, protein biomarkers have proven useful in drug discovery and development, as tools for target discovery and evaluation of a drug’s mechanism of action, and in therapies for prevention, early detection, diagnosis, and treatment of disease. Although single markers are in use, more widespread adoption will probably require a multiplexed panel capable of detecting and measuring biomarkers accurately, inexpensively, and easily in biological samples that are highly complex.

Affymetrix Launches Advanced RNA Amplification Technology for Whole-Genome Expression Analysis of FFPE Samples

Affymetrix, Inc. (NASDAQ:AFFX) announced today the availability of SensationPlus™ FFPE Amplification and 3’ IVT Labeling Kit (SensationPlus™ FFPE Reagent Kit), consisting of RNA amplification and labeling modules, to enable gene expression profiling of formalin-fixed, paraffin-embedded (FFPE) samples on GeneChip® 3’ IVT arrays and Almac XcelTM Array for disease clinical research and retrospective studies.

Aushon Launches Cira Multiplex Protein Biomarker Platform

Aushon announced the launch of Cira, a new multiplex immunoassay platform that achieves the sensitivity and reproducibility of singleplex ELISA, while substantially improving ease of use and leveraging the benefits of parallel analysis. The system’s revolutionary design produces faster results at a lower cost per sample and higher throughput without compromising the quality or consistency scientists need for their clinical studies.

Aushon to Launch New Multiplex Immunoassay Platform

Aushon announced its plans recently for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level performance. Aushon’s ultra-precise microarray printing, novel assay design, astronomy-grade imaging and advanced analytics provide the sensitivity and reproducibility of single-plexed ELISA in a multiplexed format. The technology is designed to meet the needs of scientists who have been unable to find a multiplexing solution that consistently delivers the required performance in their studies.

RiboMed Launches Improved Prognostic Multi Biomarker Epigenetic Test for Brain Cancer

RiboMed Clinical Services Laboratory (RCSL), a CLIA-certified subsidiary of RiboMed Biotechnologies, recently announced the release of a multi-marker methylation prognostic test for grading gliomas, the most common type of brain cancer. The test robustly analyzes 8 genes for differential methylation on FFPE (Formalin Fixed Paraffin Embedded) tumor samples to determine the G-CIMP (Glioma CpG Island Methylation Phenotype) score. The G-CIMP score correlates with patient survival and provides a new tool for physicians as they plan the patient’s treatment. This unique multiple DNA Methylation biomarker test, developed and validated by RCSL and commercialized and marketed by Castle Biosciences, Inc (Friendswood, TX), offers significant improvements in sensitivity, patient sample requirements and reproducibility over the bisulfite DNA methylation platform. These improvements were achieved by utilizing RiboMed’s proprietary and patented bisulfite-free Abscription®-based MethylMeter® platform.